Glutamatergic hypofunction occurs in Alzheimer's disease (AD). MK801, a noncompetitive blocker of glutamate N-methyl-D-aspartate receptors, was used to disrupt the cognitive performance of rats trained on a delayed nonmatching to sample radial maze task. Drugs which act by blocking serotonin (5-HT) receptors were evaluated for their ability to reduce the cognitive impairment produced by MK801. Specifically, WAY-100635, a selective 5-HT 1A receptor antagonist, buspirone, a 5-HT 1A partial agonist, ritanserin, a 5-HT 2 antagonist, and ondansetron, a 5-HT 3 antagonist, were assessed. In addition, the muscarinic agonist arecoline was evaluated for its potential cognitive benefit in this model. It was found that WAY-100635 significantly reduced the cognitive impairment induced by MK801. Treatment with single doses of ritanserin, ondansetron, or arecoline in combination with MK801 did not result in a cognitive impairment, indicating that these drugs attenuated the MK801 impairment. The combination of buspirone and MK801 resulted in an inability of the animals to complete the task. These results suggest that interactions between 5-HT and glutamate may mediate the beneficial effects of reducing cognitive impairment and that 5-HT antagonists, especially selective 5-HT 1A antagonists, may be useful in treating AD. Further, it is indicated that the MK801 model of cognitive impairment may add to the armamentarium of tools available to predict treatment efficacy in AD.
INTRODUCTION
The depletion of glutamate in the hippocampal formation (Hyman, Van Hoesen, & Damasio, 1987) as well as in the temporal cortex (Procter, Palmer, Francis, Lowe, Neary, Murphy, Doshi, & Bowen, 1988) has been demonstrated in Alzheimer's disease (AD). There are mixed findings for excitatory amino acid markers in AD brains, but analyzing a dense glutamatergic region such as the perforant path terminals (Hyman et al., 1987) or early staged AD tissue and 3-h postmortem AD tissue (Procter et al., 1988) strengthens the potential role of glutamatergic depletion in AD (Greenamyre & Young, 1989) . Glutamate is required for neuroplastic changes in animals which have been associated with learning, such as long-term potentiation (LTP) in hippocampal neurons (Collingridge & Singer, 1990) . LTP can be blocked in vivo by intracerebroventricular administration of a competitive NMDA antagonist, AP5, which also produced an impairment of place learning, but not visual discrimination, in the
